CompanyGraph
Kissei Pharmaceutical Co. Ltd.
4547 · Japan
Price data from its KSPHF listing on OTC, quoted in USD
kissei.co.jpFinancials as of FY2026
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.23B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.34: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.86%Above 5Y avg (2.49%)
Annual Rate
JPY 200.00Paid semi-annual
Payout Ratio
36.2%Sustainable
Payback Period
0.2 yr
Next Ex-Dividend
Sep 29, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
194.62BJPY1.23B · vs all stocks (USD)
Trailing P/E
12.41xRevenue (TTM)
98.60BJPY622.35M · vs all stocks (USD)
Profit Margin
14.18%Beta
-0.1620xvs all stocks
52-Week Change
-4.08%vs all stocks
Forward Annual Dividend Yield
4.86%vs all stocks
Market Capitalization
194.62BJPY1.23B · vs all stocks (USD)
Enterprise Value
119.25BJPY752.64M · vs all stocks (USD)
Trailing P/E
12.41xForward P/E
18.69xPrice to Sales (TTM)
1.73xPrice to Book (MRQ)
0.7448xEnterprise to Revenue
1.21xEnterprise to EBITDA
167.42xProfit Margin
14.18%Operating Margin
4.69%Return on Assets (TTM)
-0.96%Return on Equity (TTM)
6.48%Revenue (TTM)
98.60BJPY622.35M · vs all stocks (USD)
Revenue per Share (TTM)
2.38KJPYUpdated Aug 20, 2026Quarterly Revenue Growth
5.40%Gross Profit (TTM)
46.17BJPY291.42M · vs all stocks (USD)
EBITDA (TTM)
3.11BJPY19.65M · vs all stocks (USD)
Net Income (TTM)
13.98BJPY88.26M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
4.50%Operating Cash Flow (TTM)
-1.49BJPY-9.37M · vs all stocks (USD)
Forward Annual Dividend Rate
200.00JPYUpdated Aug 20, 2026Forward Annual Dividend Yield
4.86%vs all stocks
Trailing Annual Dividend Rate
160.00JPYUpdated Aug 20, 2026Trailing Annual Dividend Yield
3.89%vs all stocks
5-Year Average Dividend Yield
2.49%vs all stocks
Payout Ratio
36.19%Minority Interest (Equity)
1.39BJPYFY2026 · Mar 31, 2026Revenue
97.41BJPYFY2026 · Mar 31, 2026Cost of Goods Sold
51.59BJPYFY2026 · Mar 31, 2026Gross Profit
45.82BJPYFY2026 · Mar 31, 2026Operating Income
-2.93BJPY-18.47M · vs all stocks (USD)
Pre-tax Income
16.89BJPYFY2026 · Mar 31, 2026Income Tax Expense
2.93BJPYFY2026 · Mar 31, 2026Net Income
13.96BJPYFY2026 · Mar 31, 2026EBIT
16.92BJPYFY2026 · Mar 31, 2026EBITDA (Income Statement)
3.11BJPYFY2026 · Mar 31, 2026Non-operating Interest Income
148.00MJPYFY2026 · Mar 31, 2026Non-operating Interest Expense
28.00MJPYFY2026 · Mar 31, 2026EPS (Basic)
331.54JPYFY2026 · Mar 31, 2026EPS (Diluted)
331.54JPYFY2026 · Mar 31, 2026Basic Shares Outstanding
41.56MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
41.56MSharesFY2026 · Mar 31, 2026Minority Interests (P&L)
-181.00MJPYFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00JPYFY2026 · Mar 31, 2026Operating Cash Flow
11.48BJPYFY2026 · Mar 31, 2026Free Cash Flow
9.98BJPYFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
53.97BJPYFY2026 · Mar 31, 2026Starting Profit (CF Statement)
16.89BJPYFY2026 · Mar 31, 2026Other Non-cash Items
-1.76BJPYFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-1.93BJPYFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-1.72BJPYFY2026 · Mar 31, 2026Capital Expenditures
-1.50BJPYFY2026 · Mar 31, 2026Net Intangibles (CF)
-753.00MJPYFY2026 · Mar 31, 2026Purchase of Investments
-2.12BJPYFY2026 · Mar 31, 2026Sale of Investments
22.12BJPYFY2026 · Mar 31, 2026Other Investing Activity
-246.00MJPYFY2026 · Mar 31, 2026Net Investing Cash Flow
18.25BJPYFY2026 · Mar 31, 2026Long-term Debt Payments
-200.00MJPYFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-30.00MJPYFY2026 · Mar 31, 2026Common Stock Repurchase
-5.22BJPYFY2026 · Mar 31, 2026Common Dividends Paid
-4.84BJPYFY2026 · Mar 31, 2026Other Financing Charges
-1.00MJPYFY2026 · Mar 31, 2026Net Financing Cash Flow
-10.29BJPYFY2026 · Mar 31, 2026Shares Outstanding
41.45MSharesUpdated Aug 20, 2026Float Shares
34.76MSharesUpdated Aug 20, 2026% Held by Insiders
22.88%vs all stocks
% Held by Institutions
23.93%vs all stocks
Total Cash (MRQ)
52.95BJPY334.22M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.28KJPYUpdated Aug 20, 2026Total Debt (MRQ)
1.25BJPY7.89M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0054xCurrent Ratio (MRQ)
6.03xBook Value per Share (MRQ)
5.53KJPYUpdated Aug 20, 2026Total Assets
275.08BJPY1.74B · vs all stocks (USD)
Total Current Assets
114.97BJPYFY2026 · Mar 31, 2026Total Liabilities
43.55BJPYFY2026 · Mar 31, 2026Total Non-current Assets
160.12BJPYFY2026 · Mar 31, 2026Total Non-current Liabilities
21.86BJPYFY2026 · Mar 31, 2026Total Current Liabilities
21.69BJPYFY2026 · Mar 31, 2026Cash & Cash Equivalents
29.06BJPYFY2026 · Mar 31, 2026Other Short-term Investments
25.37BJPYFY2026 · Mar 31, 2026Accounts Receivable
30.76BJPYFY2026 · Mar 31, 2026Inventory
25.52BJPYFY2026 · Mar 31, 2026Accounts Payable
6.66BJPYFY2026 · Mar 31, 2026Short-term Debt
1.25BJPYFY2026 · Mar 31, 2026Other Current Liabilities
5.50BJPYFY2026 · Mar 31, 2026Other Non-current Liabilities
484.00MJPYFY2026 · Mar 31, 2026Common Stock (Book)
24.36BJPYFY2026 · Mar 31, 2026Retained Earnings
136.25BJPYFY2026 · Mar 31, 2026Total Shareholders' Equity
231.53BJPY1.46B · vs all stocks (USD)
Treasury Stock
15.51BJPYFY2026 · Mar 31, 202652-Week Low
3.50KJPYUpdated Aug 20, 202652-Week High
5.04KJPYUpdated Aug 20, 202652-Week Change
-4.08%vs all stocks
Beta
-0.1620xvs all stocks
50-Day MA
4.08KJPYUpdated Aug 20, 2026200-Day MA
4.40KJPYUpdated Aug 20, 2026Avg 10-Day Volume
69.17KSharesUpdated Aug 20, 2026Avg 30-Day Volume
76.26KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
331.70JPYUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Three years of positive free cash flow, with the 50-week average above the 200-week.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 88,255,099.972Operating Cash Flow (USD, TTM): -9,372,726
Financial Health
Altman Z-Score 4.34: safe zoneNotable
Altman Z-Score: 4.34
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.23B, above the global median of $1.15BNotable
Market cap (USD): 1,228,363,113.17Global Median: 1,146,734,693.424
Revenue is $622.35M, above the global median of $520.53MNotable
Revenue (USD): 622,349,001.553Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Viyash Scientific Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sequent Scientific Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Carsgen Therapeutics Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Artivion Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Hongyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MannKind Corporation
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Novartis AG
2 interpretationsThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAMulti-Year Revenue, Profit, And Income Growth
Torrent Pharmaceuticals Ltd.
2 interpretationsThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAMulti-Year Revenue, Profit, And Income Growth
Catalyst Pharmaceuticals Inc.
2 interpretationsThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAMulti-Year Revenue, Profit, And Income Growth